FOXD3 controls pluripotency through modulating enhancer activity by Yong, JS et al.
© Stem Cell Investigation. All rights reserved. Stem Cell Investig 2016;3:17sci.amegroups.com
Page 1 of 4
Pluripotent stem cell governs the potential for full and 
proper range of early development. These cell fate 
transitions are mostly achieved by the sequential binding 
of transcription factors (TFs) and the associated changes in 
gene expression. Enhancers are the major DNA elements 
that are involved in the regulation of cell-specific gene 
expression. Thus, to understand the drivers of these 
transitions and the exact mechanisms for these cells to 
retain their pluripotency, it is essential to look deeper 
into these enhancers and how they work with various 
TFs. Krishnakumar et al. recently identified that forkhead 
TF FOXD3 binds to a differential set of enhancers in 
embryonic stem cells (ESCs) and epiblast cells (EpiCs). 
FOXD3 acts as a pioneer TF and precedes the binding of 
other TFs to regulate gene expression by the regulation 
of local chromatin structure and nucleosomes. Notably, 
FOXD3 interacts with both the SW1/SNF chromatin 
remodelling complex ATPase BRG1 and histone deacetylase 
1/2 (HDAC1/2), in order to keep expression in check by 
activating and simultaneously suppressing different sets of 
genes. 
Embryonic development is a biological process that 
promotes the differentiation of pluripotent stem cells into 
specific cell lineages through several sequential inductive 
events. The ability of progenitor cell intermediates to 
respond to environmental inductive cues that drive cell-
specific expression programmes is called developmental 
competence. The mechanism that induces developmental 
competence in ESCs in a context-dependent manner is as 
yet elusive (1).
The activity of TFs and the epigenetic priming of 
enhancers, are key contributors for the induction of cellular 
competence in development (1,2). Epigenetic patterning of 
enhancers, which are regulatory DNA elements that modulate 
gene expression, occurs prior to cell fate decisions and 
involves the DNA methylation status, the binding of pioneer 
TFs to enhancers and existing histone modifications (2). 
Understanding the molecular events underlying the 
epigenetic priming of enhancers could prove useful to 
develop strategies to manipulate induced pluripotent stem 
cells for the enormous therapeutic potential due to their 
remarkable ability to self-renew (2,3). 
Furthermore, pioneer factors are a subset of TFs which 
interact with target genes prior to binding of other TFs 
for gene expression (4). It has been proposed that binding 
of pioneer TFs to specific enhancers promotes future gene 
expression through nucleosome repositioning which ensures 
the subsequent recruitment of other TFs and regulatory 
proteins and assembly of transcriptional complexes. Also, 
it is worth mentioning that these molecules access compact 
chromatin without the involvement of chromatin modifiers 
and remodellers (4,5).
Multiple pioneer factors such as FOXA1, FOXA2, and 
FOXD3 belong to the superfamily of Forkhead box (FOX) 
TFs (1,6). The Forkhead box proteins are characterised 
by an evolutionary conserved ‘forkhead’ or ‘winged helix’ 
DNA-binding domain. The FOX proteins are involved in 
orchestrating temporal and spatial gene expression during 
embryonic development and homeostasis of adult tissues. 
Besides, they regulate fundamental biological processes 
such as cell cycle progression, proliferation, differentiation, 
metabolism, senescence, apoptosis and survival (7). 
Additionally, these transcriptional regulators play a crucial 
role in cancer since they are implicated in cancer initiation, 
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progression and chemoresistance (7). 
In fact, several studies have shown that pioneer 
factors govern the dynamics of enhancers for specific 
gene expression in pluripotent stem cell potential, cell 
fate transitions, lineage choice and differentiation (8,9). 
A previous study by Wang et al., has demonstrated that 
FOXA1 and FOXA2 are involved in the epigenetic priming 
of enhancers that leads to the acquisition of developmental 
competence during endodermal lineage diversification (1). 
In addition, FOXA1 mainly operates through enhancers 
binding and trigger transcriptional competency of target 
genes, through initial chromatin decompaction (10). 
FOXA1 also plays a role in the organ differentiation 
and developments, and has also been involved in cancer 
including breast and prostate cancer (10,11). In the other 
hand, FOXD3 is involved in pluripotency maintenance 
in human ESCs, in promoting epithelial-to-mesenchymal 
transition during neural crest specification, in regulating the 
balance between melanocyte and Schwann cell development, 
and in the regulation of a set of differentiation-associated 
genes along with NFATc3 in ESCs (12-15). In addition, 
FOXD3 acts as tumour suppressor in a wide range of human 
cancers, such as hepatocellular carcinoma, non-small cell 
lung cancer, and breast cancer (16-18). Recently, FOXD3 is 
in the limelight for being involved in the regulation of stem 
cell pluripotency by binding to different enhancer marks 
and subsequently manipulating transcriptional competency 
of specific genes (6,19,20).
A recent study by Krishnakumar et al., described the 
epigenetic mechanism underlying enhancer priming 
and regulation of pluripotent stem cell potential during 
differentiation of ESCs to EpiCs that takes place in the 
early stages of mammalian embryonic development (6). 
The results have uncovered a major role of FOXD3 in 
fine-tuning gene expression through coordinated activation 
and repression of enhancer activity in a context-dependent 
manner prior to gastrulation and germ layer foundation. 
First of all, through a highly specialised reporter 
system that follows enhancer activity during ESCs to 
EpiCs transition with differential cell culture conditions 
and chromatin immunoprecipitation (ChIP)-sequencing, 
Krishnakumar et al. has observed the highly interchangeable 
nature of this developmental stage as a result of enhancer 
transition from active to primed states and vice versa (6). The 
establishment of epigenetic marks such as H3K27ac was also 
highly dynamic and independent of the most common HAT 
protein found at enhancer regions, P300. Next, ChromHMM 
was used to analyse the occurrence of four epigenetic marks 
at enhancer sites during six cell states. Again, it was observed 
that distinct cell states were characterised by the presence of 
different enhancer marks. In addition, FOXD3 binding motif 
was found to be highly enriched during these cell transitions, 
which turn the research focus towards it.
Moreover, by ChIP-seq for FOXD3-3X-FLAG, de novo 
motif finding and FIMO analysis with FOXD3 position weight 
matrix (PWM), it was reflected that FOXD3 translocates itself 
during ESCs to EpiCs transition and interacts with genomic 
regions close to different genes in the two cell states prior to 
their maximal expression (6). Furthermore, ChiP-seq analysis 
showed that FOXD3 binding precedes the recruitment of 
other crucial regulatory factors, such as OCT4, which confirms 
that FOXD3 regulates chromatin structures to ensure future 
binding of other TFs.
Ev idence  obta ined  f rom FAIRE-seq ,  DNAse l 
hypersensitivity (HS)-seq, high-resolution micrococcal 
nuclease (MNase)-ChIP-seq, a conditional KO model for 
FOXD3 with a Tamoxifen-inducible CRE recombinase 
driven off an ubiquitous promoter, IP of FOXD3 and 
expression microarray analysis indicated that FOXD3 
promotes enhancer activity through the nucleosome 
repositioning at H3K4me1 sites in specific genomic regions 
in a precise manner during ESCs to EpiCs transition which 
primes them for subsequent activation (6). In the same 
way, FOXD3 sustains hypoacetylation of neighbouring 
genes to repress them which restricts their expression in a 
precise manner until occurrence of an appropriate scenario. 
ChIP-qPCR confirmed that FOXD3 is responsible for 
recruiting BRG1, a crucial component of the SWI/SNF 
nucleosome remodeling complex, to enhancers. However, 
BRG1 maintenance at these regulatory sites is FOXD3 
independent. FOXD3 primes enhancers to modulate gene 
expression, so that they can be either activated or repressed in 
future scenarios based on specific induction signals. FOXD3 
recruits and interacts with HDAC1/2 at enhancer sites to 
fine-tune modulation of gene expression. Finally, different 
combinations of IP-western blot and sequential ChIP 
confirmed that BRG1, HDAC1 and FOXD3 interact with 
each other and form a single complex. This protein complex 
is involved in epigenetic priming of enhancers which are 
simultaneously repressed by the epigenetic mark H3K27ac.
These findings have broaden the current understanding 
of the mechanisms that tightly regulate transcriptional 
activity and gene expression during stem cell transition 
states in embryonic development. However, a study led 
by Respuela et al. (20) that addresses the same issue was 
published simultaneously in the same scientific journal. 
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Interestingly, both studies reached different conclusions 
about the role of FOXD3 in pluripotency and early 
differentiation of mESCs (21). The main reason that 
explains this divergence between both studies is the fact 
that these studies differ in certain parameters included in 
their respective experimental designs selected to analyse this 
molecular scenario, such as distinct cell culture conditions, 
methodological approaches, and algorithms/criteria 
applied for bioinformatical data analysis. Due to opposing 
conclusions being reached, these results provided by both 
groups will have to be confirmed by further studies.
The study of the molecular events that orchestrate the 
complex processes, which conduct mammalian embryonic 
development, will provide key insights that could be 
applied to unravel the as yet unknown aspects that rule 
the onset of diseases such as cancer. The mechanisms that 
are involved in early development are crucial to maintain 
homeostasis and health of the later differentiated cells. 
Their unexpected perturbation is responsible for the rise 
of disease phenotypes. Acquiring advanced knowledge 
about the system at equilibrium will pave the way for the 
development of more effective therapeutic strategies to 
overcome these diseases. Finally, these insights will provide 
better tools to manipulate induced pluripotent stem cells 
(iPSCs) and their therapeutic potentials in order to improve 
tissue transplantation approaches to treat diseases through 
regenerative medicine.
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